Venadaparib is under clinical development by Idience and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Venadaparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IDX-1197 (NOV1401) is under development for the treatment of solid tumors including high-grade serious ovarian cancer, breast cancer, prostate cancer, gastroesophageal junction, endometrial cancer, fallopian tube cancer, uterine cancer and gastric cancer. It is formulated as capsule and administered orally. It acts by targeting PARP-1 and PARP-2.
Idience is a science-driven biopharmaceutical company that changes oncology patients’ quality of life. The company is headquartered in Seoul, South Korea.
For a complete picture of Venadaparib’s drug-specific PTSR and LoA scores, buy the report here.